Safety and Efficacy of Talampanel in Glioblastoma Multiforme
Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to estimate overall survival for adult patients with newly
diagnosed glioblastoma multiforme treated with talampanel during radiation therapy with
concurrent and adjuvant temozolomide. This study will also determine the toxicity and
toxicity rate of talampanel for this therapeutic regimen.
Phase:
Phase 2
Details
Lead Sponsor:
Teva Branded Pharmaceutical Products R&D, Inc. Teva Pharmaceutical Industries